General Information of Drug (ID: DMMEH12)

Drug Name
L-006235-1 Drug Info
Synonyms
294623-49-7; L 006235; CHEMBL426819; N-(1-((cyanomethyl)carbamoyl)cyclohexyl)-4-(2-(4-methylpiperazin-1-yl)thiazol-4-yl)benzamide; L006235; N-[1-[[(Cyanomethyl)amino]carbonyl]cyclohexyl]-4-[2-(4-methyl-1-piperazinyl)-4-thiazolyl]benzamide; L-006235-1; SCHEMBL6183485; CTK8E9371; BDBM19854; DTXSID90432735; MolPort-023-276-653; BCP28510; ZINC3993799; AKOS024457410; basic piperazine-containing compound, 1; NCGC00371088-01; RT-013466; CRA-013783/L-006235; J-017526; L-006235; L-006,235
Indication
Disease Entry ICD 11 Status REF
Osteoarthritis FA00-FA05 Preclinical [1]
Cross-matching ID
PubChem CID
9912381
CAS Number
CAS 294623-49-7
TTD Drug ID
DMMEH12

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Cathepsin K (CTSK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Odanacatib DM1EO3G Osteoporosis FB83.0 Phase 3 [3]
SAR-114137 DMZ1XR5 Pain MG30-MG3Z Phase 1 [4]
VEL-0230 DMDSC63 Rheumatoid arthritis FA20 Phase 1 [5]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [6]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [6]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [6]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [7]
PMID27998201-Compound-15 DMOB8LU Pain MG30-MG3Z Patented [6]
Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 DM1SH5R Pain MG30-MG3Z Patented [6]
PMID27998201-Compound-8 DMZK0SY N. A. N. A. Patented [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin L (CTSL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KGP94 DM2NZ6K Coagulation defect 3B10.0 Clinical trial [8]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [6]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [6]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [6]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [7]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [6]
Phenylalanine derivative 1 DMVYP8K Glioma 2A00.0 Patented [6]
PMID27998201-Compound-7 DMU4QYR Abdominal aortic aneurysm BD50.4 Patented [6]
PMID27998201-Compound-6 DM0LGTY N. A. N. A. Patented [6]
PMID27998201-Compound-1 DM5QH4C Coronavirus infection 1D92 Patented [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin B (CTSB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [6]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [6]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [6]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [6]
PMID27998201-Compound-11 DMTV5NU Metastatic cancer 2D50-2E2Z Patented [6]
PMID27998201-Compound-2 DMMAE3C Alzheimer disease 8A20 Patented [6]
PMID27998201-Compound-22 DMS9QA7 Alzheimer disease 8A20 Patented [6]
PMID27998201-Compound-13 DMZHIM8 Hepatic fibrosis DB93.0 Patented [6]
Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 DMZ4B3W Cerebral ischemia 8B11 Patented [6]
PMID27998201-Compound-24 DM25BNZ Glioma 2A00.0 Patented [6]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin S (CTSS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RG7625 DMDGPKS Autoimmune disease 4A40-4A45 Phase 2 [9]
SAR-114137 DMZ1XR5 Pain MG30-MG3Z Phase 1 [4]
VBY- 891 DMTKPH4 Autoimmune diabetes 5A10 Phase 1 [10]
VBY- 036 DMULRYC Neuropathic pain 8E43.0 Phase 1 [11]
VBY-129 DM4YIWK Autoimmune diabetes 5A10 Phase 1 [12]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [6]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [6]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [6]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [7]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin B (CTSB) TTF2LRI CATB_HUMAN Inhibitor [2]
Cathepsin K (CTSK) TTDZN01 CATK_HUMAN Inhibitor [2]
Cathepsin L (CTSL) TT36ETB CATL1_HUMAN Inhibitor [2]
Cathepsin S (CTSS) TTUMQVO CATS_HUMAN Inhibitor [2]

References

1 Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone. 2012 Jun;50(6):1250-9.
2 Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43.
3 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
4 From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
5 Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4.
6 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
7 An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
8 Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
11 Clinical pipeline report, company report or official report of ViroBay.
12 Clinical pipeline report, company report or official report of ViroBay.